Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling

Andreas Papapetropoulos, Paola Piccardoni, Giuseppe Cirino, Mariarosaria Bucci, Raffaella Sorrentino, Carla Cicala, Kirk Johnson, Venetia Zachariou, William C. Sessa, Dario C. Altieri

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The signaling pathway initiated by factor Xa on vascular endothelial cells was investigated. Factor Xa stimulated a 5- to 10-fold increased release of nitric oxide (NO) in a dose-dependent reaction (0.1-2.5 μg/ml) unaffected by the thrombin inhibitor hirudin but abolished by active site inhibitors, tick anticoagulant peptide, or Glu-Gly-Arg-chloromethyl ketone. In contrast, the homologous clotting protease factor IXa or another endothelial cell ligand, fibrinogen, was ineffective. A factor Xa inter- epidermal growth factor synthetic peptide L 83 FTRKL 88 (G) blocking ligand binding to effector cell protease receptor-1 inhibited NO release by factor Xa in a dose-dependent manner, whereas a control scrambled peptide KFTGRLL was ineffective. Catalytically active factor Xa induced hypotension in rats and vasorelaxation in the isolated rat mesentery, which was blocked by the NO synthase inhibitor L-N(G)-nitroarginine methyl ester (L-NAME) but not by D- NAME. Factor Xa/NO signaling also produced a dose-dependent endothelial cell release of interleukin 6 (range 0.55-3.1 ng/ml) in a reaction inhibited by L- NAME and by the inter-epidermal growth factor peptide Leu 83 -Leu 88 but unaffected by hirudin. Maximal induction of interleukin 6 mRNA required a brief, 30-min stimulation with factor Xa, unaffected by subsequent addition of tissue factor-pathway inhibitor. These data suggest that factor Xa- induced NO release modulates endothelial cell-dependent vasorelaxation and cytokine gene expression. This pathway requiring factor Xa binding to effector cell protease receptor-1 and a secondary step of ligand-dependent proteolysis may preserve an anti-thrombotic phenotype of endothelium but also trigger acute phase responses during activation of coagulation in vivo.

Original languageEnglish (US)
Pages (from-to)4738-4742
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume95
Issue number8
DOIs
StatePublished - Apr 14 1998
Externally publishedYes

Fingerprint

Factor Xa
Hypotension
Nitric Oxide
Cytokines
Gene Expression
Endothelial Cells
Hirudins
Peptide Hydrolases
NG-Nitroarginine Methyl Ester
Ligands
Epidermal Growth Factor
Vasodilation
Interleukin-6
Factor IXa
Controlled Hypotension
Peptides
Acute-Phase Reaction
Mesentery
Blood Coagulation Factors
Nitric Oxide Synthase

ASJC Scopus subject areas

  • General

Cite this

Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. / Papapetropoulos, Andreas; Piccardoni, Paola; Cirino, Giuseppe; Bucci, Mariarosaria; Sorrentino, Raffaella; Cicala, Carla; Johnson, Kirk; Zachariou, Venetia; Sessa, William C.; Altieri, Dario C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 8, 14.04.1998, p. 4738-4742.

Research output: Contribution to journalArticle

Papapetropoulos, A, Piccardoni, P, Cirino, G, Bucci, M, Sorrentino, R, Cicala, C, Johnson, K, Zachariou, V, Sessa, WC & Altieri, DC 1998, 'Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling', Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4738-4742. https://doi.org/10.1073/pnas.95.8.4738
Papapetropoulos, Andreas ; Piccardoni, Paola ; Cirino, Giuseppe ; Bucci, Mariarosaria ; Sorrentino, Raffaella ; Cicala, Carla ; Johnson, Kirk ; Zachariou, Venetia ; Sessa, William C. ; Altieri, Dario C. / Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. In: Proceedings of the National Academy of Sciences of the United States of America. 1998 ; Vol. 95, No. 8. pp. 4738-4742.
@article{78cfb70af77e48c2a78715b814a2ae7e,
title = "Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling",
abstract = "The signaling pathway initiated by factor Xa on vascular endothelial cells was investigated. Factor Xa stimulated a 5- to 10-fold increased release of nitric oxide (NO) in a dose-dependent reaction (0.1-2.5 μg/ml) unaffected by the thrombin inhibitor hirudin but abolished by active site inhibitors, tick anticoagulant peptide, or Glu-Gly-Arg-chloromethyl ketone. In contrast, the homologous clotting protease factor IXa or another endothelial cell ligand, fibrinogen, was ineffective. A factor Xa inter- epidermal growth factor synthetic peptide L 83 FTRKL 88 (G) blocking ligand binding to effector cell protease receptor-1 inhibited NO release by factor Xa in a dose-dependent manner, whereas a control scrambled peptide KFTGRLL was ineffective. Catalytically active factor Xa induced hypotension in rats and vasorelaxation in the isolated rat mesentery, which was blocked by the NO synthase inhibitor L-N(G)-nitroarginine methyl ester (L-NAME) but not by D- NAME. Factor Xa/NO signaling also produced a dose-dependent endothelial cell release of interleukin 6 (range 0.55-3.1 ng/ml) in a reaction inhibited by L- NAME and by the inter-epidermal growth factor peptide Leu 83 -Leu 88 but unaffected by hirudin. Maximal induction of interleukin 6 mRNA required a brief, 30-min stimulation with factor Xa, unaffected by subsequent addition of tissue factor-pathway inhibitor. These data suggest that factor Xa- induced NO release modulates endothelial cell-dependent vasorelaxation and cytokine gene expression. This pathway requiring factor Xa binding to effector cell protease receptor-1 and a secondary step of ligand-dependent proteolysis may preserve an anti-thrombotic phenotype of endothelium but also trigger acute phase responses during activation of coagulation in vivo.",
author = "Andreas Papapetropoulos and Paola Piccardoni and Giuseppe Cirino and Mariarosaria Bucci and Raffaella Sorrentino and Carla Cicala and Kirk Johnson and Venetia Zachariou and Sessa, {William C.} and Altieri, {Dario C.}",
year = "1998",
month = "4",
day = "14",
doi = "10.1073/pnas.95.8.4738",
language = "English (US)",
volume = "95",
pages = "4738--4742",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling

AU - Papapetropoulos, Andreas

AU - Piccardoni, Paola

AU - Cirino, Giuseppe

AU - Bucci, Mariarosaria

AU - Sorrentino, Raffaella

AU - Cicala, Carla

AU - Johnson, Kirk

AU - Zachariou, Venetia

AU - Sessa, William C.

AU - Altieri, Dario C.

PY - 1998/4/14

Y1 - 1998/4/14

N2 - The signaling pathway initiated by factor Xa on vascular endothelial cells was investigated. Factor Xa stimulated a 5- to 10-fold increased release of nitric oxide (NO) in a dose-dependent reaction (0.1-2.5 μg/ml) unaffected by the thrombin inhibitor hirudin but abolished by active site inhibitors, tick anticoagulant peptide, or Glu-Gly-Arg-chloromethyl ketone. In contrast, the homologous clotting protease factor IXa or another endothelial cell ligand, fibrinogen, was ineffective. A factor Xa inter- epidermal growth factor synthetic peptide L 83 FTRKL 88 (G) blocking ligand binding to effector cell protease receptor-1 inhibited NO release by factor Xa in a dose-dependent manner, whereas a control scrambled peptide KFTGRLL was ineffective. Catalytically active factor Xa induced hypotension in rats and vasorelaxation in the isolated rat mesentery, which was blocked by the NO synthase inhibitor L-N(G)-nitroarginine methyl ester (L-NAME) but not by D- NAME. Factor Xa/NO signaling also produced a dose-dependent endothelial cell release of interleukin 6 (range 0.55-3.1 ng/ml) in a reaction inhibited by L- NAME and by the inter-epidermal growth factor peptide Leu 83 -Leu 88 but unaffected by hirudin. Maximal induction of interleukin 6 mRNA required a brief, 30-min stimulation with factor Xa, unaffected by subsequent addition of tissue factor-pathway inhibitor. These data suggest that factor Xa- induced NO release modulates endothelial cell-dependent vasorelaxation and cytokine gene expression. This pathway requiring factor Xa binding to effector cell protease receptor-1 and a secondary step of ligand-dependent proteolysis may preserve an anti-thrombotic phenotype of endothelium but also trigger acute phase responses during activation of coagulation in vivo.

AB - The signaling pathway initiated by factor Xa on vascular endothelial cells was investigated. Factor Xa stimulated a 5- to 10-fold increased release of nitric oxide (NO) in a dose-dependent reaction (0.1-2.5 μg/ml) unaffected by the thrombin inhibitor hirudin but abolished by active site inhibitors, tick anticoagulant peptide, or Glu-Gly-Arg-chloromethyl ketone. In contrast, the homologous clotting protease factor IXa or another endothelial cell ligand, fibrinogen, was ineffective. A factor Xa inter- epidermal growth factor synthetic peptide L 83 FTRKL 88 (G) blocking ligand binding to effector cell protease receptor-1 inhibited NO release by factor Xa in a dose-dependent manner, whereas a control scrambled peptide KFTGRLL was ineffective. Catalytically active factor Xa induced hypotension in rats and vasorelaxation in the isolated rat mesentery, which was blocked by the NO synthase inhibitor L-N(G)-nitroarginine methyl ester (L-NAME) but not by D- NAME. Factor Xa/NO signaling also produced a dose-dependent endothelial cell release of interleukin 6 (range 0.55-3.1 ng/ml) in a reaction inhibited by L- NAME and by the inter-epidermal growth factor peptide Leu 83 -Leu 88 but unaffected by hirudin. Maximal induction of interleukin 6 mRNA required a brief, 30-min stimulation with factor Xa, unaffected by subsequent addition of tissue factor-pathway inhibitor. These data suggest that factor Xa- induced NO release modulates endothelial cell-dependent vasorelaxation and cytokine gene expression. This pathway requiring factor Xa binding to effector cell protease receptor-1 and a secondary step of ligand-dependent proteolysis may preserve an anti-thrombotic phenotype of endothelium but also trigger acute phase responses during activation of coagulation in vivo.

UR - http://www.scopus.com/inward/record.url?scp=13144262813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13144262813&partnerID=8YFLogxK

U2 - 10.1073/pnas.95.8.4738

DO - 10.1073/pnas.95.8.4738

M3 - Article

C2 - 9539808

AN - SCOPUS:13144262813

VL - 95

SP - 4738

EP - 4742

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -